From March 27 to 31, 2025, the annual Zhongguancun Forum Conference with the theme "New Quality Productivity and Global Technological Cooperation" was grandly held in Beijing, focusing onAI Large Model、Embodied Intelligence、Quantum Technology、Biomedical、6G、Brain-Computer InterfaceIn cutting-edge fields, there are 10 brand forums and 50 innovation forums, delving into the advancements of frontier technologies and industrial development trends. The conference also unveiled Beijing's AI innovation application achievements and significant open-source results for the first time, showcasing Beijing's latest breakthroughs in AI technology empowering various industries.
This year's "Government Work Report" emphasizes the importance of artificial intelligence and large models, proposing to continuously advance the "AI+" initiative and support the widespread application of large models. Against this backdrop,METiS TechBio, as an innovative biotechnology company driven by AI in drug delivery and drug discovery, presented the latest advancements in AI-empowered drug delivery at this forum.Deputy Director of the High-Tech Department of the National Development and Reform CommissionZhao Zhidan and his entourage visit the METiS TechBio booth
World's Leading AI Drug Delivery PlatformDrug delivery is a crucial aspect of the pharmaceutical industry, but traditional delivery methods face numerous challenges, particularly in precisely delivering drugs to organs other than the liver, such as the lungs, muscles, brain, and tumor sites. METiS TechBio innovatively utilizes artificial intelligence to analyze vast amounts of interdisciplinary data and optimize the design of nanomaterials, enhancing the precision and efficiency of drug delivery.If the release of DeepSeek-R1刷新了人们对中国大模型的认知, then METiS TechBio has pioneered the application of AI-driven large models in the field of drug delivery, offering new possibilities for precision medicine.In response to the long-standing challenge of lacking open-source data and mature algorithms, METiS TechBio started from scratch and innovatively developed AI algorithms for the generation and design of ionizable lipids and LNP nanomaterial simulations. Combined with world-leading high-throughput experimental techniques and animal validation platforms, they have established a unique advantage in data and algorithms.Leveraging advanced machine learning and deep learning algorithms, METiS TechBio continuously optimizes the design and development of drug delivery systems.Independently developed by the companyThe three major innovative platforms, AiLNP, AiRNA, and AiTEM, focus on nucleic acid delivery systems, mRNA optimization, and small molecule formulation design, respectively, achieving significant improvements in R&D efficiency and precision, and have been successfully selected.「Top 30 AIGC Application Innovations in 2024」List。"SpaceX of the Pharmaceutical Industry": Driving a New Paradigm of AI-Powered Drug DeliveryAt the Zhongguan Village Forum booth, experimental data displayed by METiS TechBio showed that its delivery materials achieved expression levels 20-30 times higher than the globally leading materials in the field of gene therapy.Dr. Lai Caida, co-founder and CEO of METiS TechBio, stated: "We hope to design different 'nano-rockets' through AI + nanomaterial delivery, like 'SpaceX in the pharmaceutical industry,' opening up a trillion-dollar new market opportunity."With the deep integration of artificial intelligence, large models, and advanced materials science, precision drug delivery and intelligent treatment will embrace broader development opportunities. The continuous innovation of METiS TechBio vividly demonstrates the limitless possibilities of AI-empowered biomedicine, supporting China's "Artificial Intelligence+" initiative with firm strides.
Learn More About METiS TechBio
